Rabbit Recombinant Monoclonal PRMT7 antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ICC/IF | WB | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Specifically mediates the symmetric dimethylation of histone H4 'Arg-3' to form H4R3me2s. Plays a role in gene imprinting by being recruited by CTCFL at the H19 imprinted control region (ICR) and methylating histone H4 to form H4R3me2s, possibly leading to recruit DNA methyltransferases at these sites. May also play a role in embryonic stem cell (ESC) pluripotency. Also able to mediate the arginine methylation of histone H2A and myelin basic protein (MBP) in vitro; the relevance of such results is however unclear in vivo.
KIAA1933, PRMT7, Protein arginine N-methyltransferase 7, Histone-arginine N-methyltransferase PRMT7, [Myelin basic protein]-arginine N-methyltransferase PRMT7
Rabbit Recombinant Monoclonal PRMT7 antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab250433 is the carrier-free version of Anti-PRMT7 antibody [EPR13495] ab181214.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
PRMT7 short for Protein Arginine Methyltransferase 7 plays an important role in the methylation of arginine residues on target proteins. It acts as a type of enzyme known for catalyzing the transfer of methyl groups. PRMT7 appears in several tissues although its expression is noted in higher amounts in brain and testis tissues. This protein weighs approximately 78 kDa and undergoes different modifications influencing its activity and localization. Researchers sometimes refer to PRMT7 simply as PRMT-7.
The activity of this protein regulates gene expression by modifying histones and non-histone proteins affecting chromatin structure. It does not typically act as part of a large complex but can associate with other proteins to achieve specific functions. PRMT7 influences processes like protein signaling RNA processing and cell cycle control illustrating its diverse roles in cellular biology.
PRMT7 participates intricately in pathways involving transcriptional regulation. It regulates pathways such as the arginine methylation pathway and is connected to transcription factor binding pathways. Its action intertwines with other methyltransferases and specific epigenetic regulators such as PRMT5 highlighting the crosstalk between different protein modification pathways within cells.
PRMT7 has a connection to cancer and neurodevelopmental disorders. Altered expression or activity of PRMT7 associates with oncogenesis making it a potential target in cancer research with some studies pointing out possible links to breast cancer. In neurodevelopmental disorders the protein's role in gene expression regulation suggests its involvement. In such conditions interactions with proteins such as FMR1 linked to Fragile X syndrome highlight the importance of understanding PRMT7's function to unravel its therapeutic implications.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-PRMT7 antibody [EPR13495] ab181214, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-PRMT7 antibody [EPR13495] (Anti-PRMT7 antibody [EPR13495] ab181214) at 1/2000 dilution
Lane 1: HepG2 cell lysate at 20 µg
Lane 2: HeLa cell lysate at 20 µg
Lane 3: 293 cell lysate at 20 µg
Lane 4: MCF7 cell lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 78 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com